v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash $ 1,076,248 $ 2,598,864
Advances on research and development contract services 29,792
Accrued interest receivable 14,367
Prepaid insurance 69,091 34,508
Other prepaid expenses and current assets 13,000 24,294
Total current assets 1,188,131 2,672,033
Deferred offering costs 174,253
Total assets 1,362,384 2,672,033
Current liabilities:    
Accounts payable and accrued expenses 115,518 143,549
Accrued offering costs 44,009
Research and development contract liabilities 61,931 94,349
Total current liabilities 221,458 237,898
Commitments and contingencies
Stockholders' equity:    
Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares - 4,375,000 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 67,045,814 shares 6,704 6,704
Additional paid-in capital 27,081,063 26,016,317
Accumulated deficit (29,446,841) (27,088,886)
Total stockholders' equity 1,140,926 2,434,135
Total liabilities and stockholders' equity $ 1,362,384 $ 2,672,033

Source